Clinical Approach to Hematuria
Comprehensive Practical Framework1. Symptom Overview
Understanding the clinical significance and classification of hematuria
Hematuria is one of the most common urological presentations in primary care and emergency settings. Microscopic hematuria is detected in approximately 2 to 31% of the adult population depending on the screening method and population studied. Gross hematuria accounts for 4 to 20% of all urological consultations and is particularly concerning as it may indicate underlying malignancy in up to 20% of cases in adults over age 50. The evaluation of hematuria requires a systematic approach to distinguish benign, self-limiting causes from potentially life-threatening conditions such as urological cancers and glomerulonephritis.
Definition
Hematuria is defined as the presence of red blood cells in the urine. Gross hematuria (also called macroscopic or visible hematuria) is blood visible to the naked eye, typically requiring greater than 1 mL of blood per liter of urine. Microscopic hematuria is defined as 3 or more red blood cells per high-power field on microscopic examination of urinary sediment from two of three properly collected specimens.
Classification by Visibility
Gross (Macroscopic) Hematuria
Appearance: Visibly red, pink, or tea-colored urine
Clinical significance: Higher likelihood of significant pathology; approximately 20% of patients over age 50 with gross hematuria have urological malignancy
Urgency: Requires prompt evaluation regardless of associated symptoms
Microscopic Hematuria
Definition: ≥3 red blood cells per high-power field on microscopy
Clinical significance: Often incidental finding; malignancy present in 2 to 5% of cases
Urgency: Evaluation guided by risk factors; may be observed in low-risk patients
Classification by Duration and Pattern
| Category | Definition | Common Causes | Clinical Significance |
|---|---|---|---|
| Transient | Single episode or resolves within days | Urinary tract infection, vigorous exercise, menstrual contamination, recent instrumentation | Often benign; may not require extensive workup if resolves and patient is low-risk |
| Persistent | Present on two or more occasions over weeks to months | Urolithiasis, bladder or kidney cancer, glomerulonephritis, benign prostatic hyperplasia | Requires complete urological and nephrological evaluation |
| Recurrent | Episodes separated by periods of normal urine | IgA nephropathy (synpharyngitic hematuria), thin basement membrane disease, intermittent stone passage | Pattern may provide diagnostic clues; requires thorough evaluation |
Classification by Timing During Urination
| Pattern | Description | Anatomical Source | Suggests |
|---|---|---|---|
| Initial hematuria | Blood at the beginning of urination, clears with continued voiding | Anterior urethra | Urethral pathology: urethritis, urethral stricture, urethral caruncle, urethral cancer |
| Terminal hematuria | Blood appears at the end of urination | Bladder neck, posterior urethra, prostate | Bladder neck lesion, posterior urethral pathology, prostatic disease |
| Total hematuria | Blood throughout entire stream | Bladder, ureter, or kidney | Upper urinary tract pathology, diffuse bladder pathology |
Classification by Source: Glomerular vs Non-Glomerular
Key Concept: Distinguishing glomerular from non-glomerular (urological) hematuria is fundamental to directing the diagnostic workup and determining whether the patient needs nephrology versus urology evaluation.
| Feature | Glomerular Hematuria | Non-Glomerular (Urological) Hematuria |
|---|---|---|
| Urine color | Tea-colored, cola-colored, or smoky brown | Bright red or pink |
| Blood clots | Absent (red blood cells lyse passing through tubules) | Often present |
| Red blood cell morphology | Dysmorphic red blood cells; acanthocytes >5% | Isomorphic (normal) red blood cells |
| Red blood cell casts | Present (pathognomonic of glomerular bleeding) | Absent |
| Proteinuria | Often significant (>500 mg/day) | Usually absent or minimal |
| Associated symptoms | Edema, hypertension, oliguria | Dysuria, flank pain, urinary frequency |
| Primary evaluation | Nephrology referral | Urology referral |
Pseudohematuria: Important Mimics
Not All Red Urine Is Hematuria
Before initiating an extensive workup, confirm true hematuria with microscopy. The following can cause red or dark urine without red blood cells:
- Hemoglobinuria — intravascular hemolysis
- Myoglobinuria — rhabdomyolysis
- Porphyria — porphyrins in urine
- Foods — beets, blackberries, rhubarb
- Medications — rifampin, phenazopyridine, nitrofurantoin
- Menstrual contamination — in women
Key Epidemiological Facts
- Prevalence of microscopic hematuria: 2 to 31% of adults (varies by population and definition)
- Malignancy rate in gross hematuria: 10 to 20% in adults over age 50
- Malignancy rate in microscopic hematuria: 2 to 5% overall; higher with risk factors
- Most common cause overall: Urinary tract infection
- Most common cause of gross hematuria requiring hospitalization: Bladder cancer
2. Pathophysiology and Mechanisms
Understanding the underlying mechanisms of hematuria
Understanding the anatomy of the urinary tract and the mechanisms by which blood enters the urine is essential for localizing the source and narrowing the differential diagnosis. Blood can enter the urine at any point from the glomerulus to the urethral meatus, and the mechanism varies depending on the underlying pathology. The urinary tract can be conceptually divided into the upper tract (kidneys and ureters) and lower tract (bladder, prostate in males, and urethra).
Anatomical Sources of Hematuria
| Anatomical Site | Structure | Common Pathologies | Typical Presentation |
|---|---|---|---|
| Glomerulus | Filtration unit of the kidney | IgA nephropathy, post-infectious glomerulonephritis, thin basement membrane disease, Alport syndrome | Dysmorphic red blood cells, red blood cell casts, proteinuria, tea-colored urine |
| Renal tubules and interstitium | Tubular system and surrounding tissue | Acute interstitial nephritis, polycystic kidney disease, papillary necrosis | Variable; may have white blood cell casts, sterile pyuria |
| Renal pelvis and ureter | Collecting system and conduit | Urolithiasis, transitional cell carcinoma, ureteropelvic junction obstruction | Colicky flank pain, isomorphic red blood cells, clots possible |
| Bladder | Urine reservoir | Bladder cancer, cystitis, radiation cystitis, bladder stones | Total hematuria, clots, storage symptoms (frequency, urgency) |
| Prostate | Male reproductive gland surrounding urethra | Benign prostatic hyperplasia, prostatitis, prostate cancer | Terminal hematuria, voiding symptoms, hematospermia |
| Urethra | Conduit from bladder to external meatus | Urethritis, urethral stricture, urethral carcinoma, trauma | Initial hematuria, urethral discharge, dysuria |
Mechanism of Glomerular Hematuria
Key Principle: In glomerular hematuria, red blood cells pass through a damaged glomerular basement membrane. As they squeeze through these defects, they become distorted, creating the characteristic dysmorphic appearance seen on microscopy.
Glomerular Basement Membrane Damage
Mechanism: Disruption of the filtration barrier allows red blood cells to escape into Bowman’s space
Examples: IgA nephropathy, lupus nephritis, anti-glomerular basement membrane disease
Result: Dysmorphic red blood cells, acanthocytes, red blood cell casts
Podocyte Injury
Mechanism: Damage to visceral epithelial cells increases permeability
Examples: Focal segmental glomerulosclerosis, minimal change disease
Result: Heavy proteinuria, often with microscopic hematuria
Inherited Structural Defects
Mechanism: Abnormal collagen or thinning of basement membrane
Examples: Thin basement membrane disease, Alport syndrome
Result: Persistent microscopic hematuria, often familial
Mechanisms of Non-Glomerular (Urological) Hematuria
| Mechanism | Pathophysiology | Associated Conditions | Clinical Features |
|---|---|---|---|
| Mucosal erosion | Disruption of urothelial lining exposes submucosal blood vessels | Bladder cancer, urolithiasis, severe cystitis | Often painless (cancer) or painful (stones, infection); may have clots |
| Vascular engorgement | Increased blood flow and fragile vessels prone to rupture | Benign prostatic hyperplasia, radiation cystitis | Intermittent hematuria, often with obstructive symptoms |
| Infection and inflammation | Inflammatory mediators increase vascular permeability; mucosal irritation | Urinary tract infection, prostatitis, urethritis | Dysuria, frequency, urgency, pyuria present |
| Trauma | Direct injury to urinary tract structures | Blunt or penetrating trauma, iatrogenic (catheterization, instrumentation) | History of injury or procedure; gross hematuria common |
| Neovascularization | Tumor angiogenesis creates friable vessels prone to bleeding | Renal cell carcinoma, bladder cancer, ureteral carcinoma | Painless hematuria, may be intermittent |
| Vascular malformation | Abnormal vessel structure prone to spontaneous bleeding | Renal arteriovenous malformation, hemangioma | Recurrent hematuria, may be massive |
How Specific Conditions Cause Hematuria
| Condition | Mechanism | Treatment Implication |
|---|---|---|
| Urinary tract infection | Bacterial invasion causes mucosal inflammation and increased vascular permeability; inflammatory cells release cytokines damaging urothelium | Antibiotics resolve infection; hematuria typically clears within days of treatment |
| Urolithiasis | Stones cause direct mucosal abrasion during passage; obstruction increases intraluminal pressure and capillary rupture | Pain control, hydration, stone passage or intervention; hematuria resolves with stone clearance |
| Bladder cancer | Tumor neovascularization creates friable vessels; tumor erosion through urothelium exposes vessels to urine | Requires cystoscopy for diagnosis; transurethral resection, intravesical therapy, or cystectomy depending on stage |
| Benign prostatic hyperplasia | Increased stromal vascularity in enlarged gland; straining to void increases venous pressure; vessels rupture with prostatic contraction | Alpha-blockers or 5-alpha reductase inhibitors may reduce bleeding episodes |
| IgA nephropathy | IgA immune complex deposition in mesangium triggers inflammation and basement membrane damage; often triggered by mucosal infections | Supportive care for mild disease; immunosuppression for progressive disease; blood pressure control is critical |
| Thin basement membrane disease | Inherited defect causing uniformly thin glomerular basement membrane allows red blood cells to pass through | Benign prognosis in most cases; reassurance; monitor for progression |
| Exercise-induced hematuria | Renal vasoconstriction during exercise increases filtration pressure; bladder trauma from repetitive impact (long-distance running); dehydration concentrates urine | Self-limited; resolves within 24 to 72 hours; adequate hydration during exercise |
| Anticoagulation-associated hematuria | Anticoagulation does not cause hematuria but unmasks underlying lesions that would otherwise not bleed significantly | Full urological workup indicated; do not attribute hematuria solely to anticoagulation |
Often Overlooked Mechanism: Anticoagulation Unmasking Pathology
A common clinical error is attributing hematuria to anticoagulant or antiplatelet therapy and stopping the workup. In fact, anticoagulation does not cause hematuria — it unmasks underlying pathology that would otherwise remain occult. Studies show that patients on anticoagulation who develop hematuria have similar rates of significant urological disease (including malignancy) as patients not on anticoagulation. Always complete a full evaluation regardless of anticoagulant use.
Understanding Red Blood Cell Morphology
Dysmorphic Red Blood Cells
Appearance: Variable size and shape; membrane blebs, budding, and fragmentation
Acanthocytes: Ring-form cells with vesicle-shaped protrusions; greater than 5% is highly specific for glomerular origin
Mechanism: Red blood cells are damaged as they squeeze through defects in the glomerular basement membrane and pass through the harsh osmotic environment of the tubules
Clinical significance: Indicates glomerular bleeding; warrants nephrology evaluation
Isomorphic Red Blood Cells
Appearance: Uniform, normal biconcave disc shape
Mechanism: Red blood cells enter the urinary tract below the nephron and are not subjected to osmotic stress
Clinical significance: Indicates non-glomerular (urological) bleeding; warrants urological evaluation including imaging and cystoscopy
Red Blood Cell Casts: Pathognomonic of Glomerular Disease
Red blood cell casts form when red blood cells become trapped in a protein matrix (Tamm-Horsfall protein) within the renal tubules. Their presence is pathognomonic of glomerular bleeding and indicates active glomerulonephritis. Red blood cell casts are fragile and degrade quickly, so urine should be examined within 30 minutes of collection for optimal detection.
3. History Taking
A comprehensive approach to eliciting the hematuria history
Red Flags — Require Urgent Evaluation
- Painless gross hematuria in patient over age 40 — high risk of urological malignancy
- Clot retention or inability to void — urological emergency
- Hemodynamic instability with hematuria — significant blood loss or sepsis
- Hematuria with new hypertension and edema — acute glomerulonephritis
- Recent pharyngitis followed by tea-colored urine — post-streptococcal glomerulonephritis or IgA nephropathy
- Flank pain with fever and hematuria — pyelonephritis or infected stone
- History of smoking with new hematuria — bladder cancer risk
- Unexplained weight loss with hematuria — malignancy workup indicated
Systematic History: The “BLOOD” Approach
Use the mnemonic “BLOOD” to ensure comprehensive history taking for hematuria:
- B — Bleeding characteristics: Color, timing during stream, presence of clots, duration, intermittent versus continuous
- L — Location clues: Associated pain location (flank, suprapubic, urethral), radiation pattern
- O — Other urinary symptoms: Dysuria, frequency, urgency, hesitancy, incomplete emptying, nocturia
- O — Onset and context: Relationship to exercise, trauma, recent infection, instrumentation, menstruation
- D — Danger signs and risk factors: Smoking history, occupational exposures, family history, weight loss, prior cancers
Targeted Questions by Suspected Cause
| Suspected Cause | Key Features | Ask This Question |
|---|---|---|
| Urinary tract infection | Dysuria, frequency, urgency, suprapubic discomfort, cloudy urine | “Do you have burning when you urinate, or do you feel like you need to go frequently or urgently?” |
| Urolithiasis | Severe colicky flank pain radiating to groin, nausea, restlessness | “Have you had sudden severe pain in your back or side that comes in waves and may travel to your groin?” |
| Bladder cancer | Painless gross hematuria, older age, smoking history | “Have you noticed blood in your urine without any pain? Have you ever smoked cigarettes?” |
| Benign prostatic hyperplasia | Weak stream, hesitancy, nocturia, incomplete emptying, terminal dribbling | “Do you have difficulty starting urination, a weak stream, or feel like your bladder doesn’t empty completely?” |
| Glomerulonephritis | Tea-colored urine, facial or peripheral edema, recent infection, foamy urine | “Is your urine tea-colored or cola-colored? Have you noticed swelling in your face, hands, or feet? Have you had a recent sore throat or skin infection?” |
| IgA nephropathy | Gross hematuria concurrent with or within 1-2 days of upper respiratory infection | “Does the blood in your urine appear during or right after you get a cold or sore throat?” (synpharyngitic hematuria) |
| Renal cell carcinoma | Classic triad (rare): flank pain, hematuria, palpable mass; often asymptomatic | “Have you had any flank pain, unexplained weight loss, fevers, or night sweats?” |
| Exercise-induced hematuria | Hematuria following strenuous exercise, resolves within 24-72 hours | “Did you do any intense exercise, such as running, cycling, or contact sports, before you noticed the blood?” |
| Trauma | History of injury, recent instrumentation or catheterization | “Have you had any recent injury to your abdomen, back, or pelvis? Have you had any recent catheter insertion or urological procedure?” |
| Inherited nephropathy | Family history of kidney disease, hematuria, deafness, or dialysis | “Does anyone in your family have kidney problems, blood in their urine, hearing loss, or require dialysis?” |
Characterizing the Bleeding
| Characteristic | Question to Ask | Clinical Significance |
|---|---|---|
| Color | “What color is your urine? Bright red, pink, tea-colored, or cola-colored?” | Bright red suggests lower tract or active bleeding; tea/cola suggests glomerular source |
| Clots | “Do you see any blood clots in your urine? What shape are they?” | Clots indicate non-glomerular bleeding; vermiform (worm-shaped) clots suggest upper tract origin |
| Timing during stream | “Does the blood appear at the beginning, end, or throughout urination?” | Initial = urethra; Terminal = bladder neck/prostate; Total = bladder or upper tract |
| Pain association | “Is there any pain associated with the bleeding?” | Painful hematuria suggests infection, stones, or cystitis; painless suggests malignancy |
| Duration and pattern | “How long have you had blood in your urine? Is it constant or does it come and go?” | Intermittent painless hematuria is classic for bladder cancer |
Medication and Substance History
Medications That May Cause or Unmask Hematuria
- Anticoagulants (warfarin, heparin, direct oral anticoagulants) — unmask underlying lesions; do not cause hematuria in normal urinary tract
- Antiplatelet agents (aspirin, clopidogrel) — similar to anticoagulants
- Cyclophosphamide — hemorrhagic cystitis from acrolein metabolite
- Nonsteroidal anti-inflammatory drugs — interstitial nephritis, papillary necrosis
- Penicillins, cephalosporins, sulfonamides — acute interstitial nephritis
- Rifampin — causes orange-red urine (not true hematuria)
Social and Occupational History
- Smoking: Single most important risk factor for bladder cancer; quantify pack-years
- Occupational exposures: Aromatic amines, benzene, dyes, rubber manufacturing, leather work, aluminum production
- Radiation history: Prior pelvic radiation increases bladder cancer risk
- Travel history: Endemic areas for schistosomiasis (Egypt, sub-Saharan Africa) — causes squamous cell bladder cancer
- Sexual history: Risk for urethritis, sexually transmitted infections
- Recreational drug use: Ketamine abuse causes hemorrhagic cystitis
Family History: Key Questions
| Family History Finding | Condition to Consider | Additional Features |
|---|---|---|
| Family members with hematuria | Thin basement membrane disease, Alport syndrome, IgA nephropathy | Autosomal dominant in thin basement membrane disease; X-linked in classic Alport |
| Early-onset kidney failure in family | Alport syndrome, polycystic kidney disease | Alport: associated hearing loss and eye abnormalities |
| Deafness in male relatives | Alport syndrome | Sensorineural hearing loss, progressive; anterior lenticonus on eye examination |
| Multiple kidney cysts in family | Autosomal dominant polycystic kidney disease | Flank pain, hypertension, hepatic cysts, intracranial aneurysms |
| Urological cancers in family | Hereditary cancer syndromes (Lynch syndrome, von Hippel-Lindau) | Young age at diagnosis, multiple primary tumors |
Risk Stratification for Urological Malignancy
The American Urological Association risk stratifies patients with microscopic hematuria to guide evaluation intensity:
- Low risk: Age less than 40, never smoker or less than 10 pack-years, 3-10 red blood cells per high-power field, no other risk factors
- Intermediate risk: Age 40-59, 10-30 pack-years, 11-25 red blood cells per high-power field, or low-risk with prior low-risk evaluation
- High risk: Age 60 or older, greater than 30 pack-years, greater than 25 red blood cells per high-power field, gross hematuria, or history of gross hematuria
4. Physical Examination
A systematic head-to-toe approach for hematuria
Systematic Framework: Use the “General to Focused” approach for complete examination of patients presenting with hematuria. Begin with overall assessment and vital signs, then systematically examine for signs of underlying cause, complications, and associated systemic disease.
General Inspection
- Appearance: Pallor (anemia from chronic blood loss), cachexia (malignancy), cushingoid features (consider iatrogenic causes or adrenal pathology)
- Hydration status: Dry mucous membranes, reduced skin turgor (dehydration may concentrate urine and exacerbate stone formation)
- Respiratory distress: May indicate fluid overload in nephritic syndrome
- Level of discomfort: Restlessness and inability to find comfortable position suggests renal colic; quiet and still suggests peritoneal irritation
- Skin: Petechiae, purpura, or ecchymoses (coagulopathy, vasculitis); rashes (systemic lupus erythematosus, Henoch-Schönlein purpura)
Vital Signs
| Vital Sign | What to Look For | Clinical Significance |
|---|---|---|
| Blood Pressure | Hypertension (systolic greater than 140 or diastolic greater than 90); hypotension | Hypertension: glomerulonephritis, polycystic kidney disease, renal artery stenosis. Hypotension: significant hemorrhage, sepsis |
| Heart Rate | Tachycardia (greater than 100 beats per minute) | May indicate pain, hypovolemia from blood loss, fever, or anxiety |
| Temperature | Fever (greater than 38°C or 100.4°F) | Urinary tract infection, pyelonephritis, infected stone, renal abscess, or systemic illness |
| Respiratory Rate | Tachypnea (greater than 20 breaths per minute) | Pain, metabolic acidosis (uremic), fluid overload with pulmonary edema |
| Oxygen Saturation | Hypoxia (less than 94% on room air) | May indicate pulmonary edema from fluid overload in acute glomerulonephritis |
Head, Eyes, Ears, and Neck
Eyes
Conjunctival pallor: Anemia from chronic blood loss
Scleral icterus: Consider hemolysis causing hemoglobinuria (not true hematuria)
Anterior lenticonus: Pathognomonic of Alport syndrome
Fundoscopy: Hypertensive retinopathy, diabetic retinopathy (associated nephropathy)
Ears and Neck
Hearing assessment: Sensorineural hearing loss in Alport syndrome
Cervical lymphadenopathy: Malignancy, infection
Jugular venous pressure: Elevated in fluid overload from renal failure or nephritic syndrome
Thyroid: Enlarged in some systemic diseases
Cardiovascular Examination
- Jugular venous pressure: Elevated suggests fluid overload (acute kidney injury, nephritic syndrome)
- Apex beat: Displaced in cardiomegaly from chronic hypertension or fluid overload
- Heart sounds: Third heart sound (S3) gallop in fluid overload; pericardial rub in uremic pericarditis
- Murmurs: New murmur may suggest endocarditis (associated with glomerulonephritis)
- Peripheral pulses: Assess for evidence of vascular disease; absent pulses may suggest atheroembolic disease
- Peripheral edema: Pitting edema of lower extremities in nephrotic syndrome or fluid overload
Respiratory Examination
- Inspection: Increased work of breathing in pulmonary edema; hemoptysis may indicate pulmonary-renal syndrome (anti-glomerular basement membrane disease, granulomatosis with polyangiitis)
- Percussion: Dullness at bases suggests pleural effusion (nephrotic syndrome, fluid overload)
- Auscultation: Bilateral crackles suggest pulmonary edema; focal findings may indicate pneumonia or hemorrhage
Abdominal and Flank Examination
Inspection
- Distension: May indicate urinary retention, ascites (nephrotic syndrome, malignancy)
- Surgical scars: Prior urological or abdominal surgery
- Flank fullness: Large renal mass or perinephric collection
Palpation
- Suprapubic tenderness: Cystitis, urinary retention with bladder distension
- Palpable bladder: Urinary retention; should not be palpable normally
- Flank tenderness: Pyelonephritis, renal abscess, obstructing ureteral stone
- Costovertebral angle tenderness: Classic finding in pyelonephritis; also seen with renal stones, renal infarction
- Renal mass: Bimanually palpable in polycystic kidney disease, large renal tumors; normal kidneys are not palpable
- Abdominal aortic aneurysm: Pulsatile mass; may cause hematuria if eroding into urinary tract
Percussion
- Costovertebral angle percussion tenderness: More sensitive than palpation for detecting renal pathology
- Suprapubic dullness: Full bladder (urinary retention)
Genitourinary Examination
Male Examination
- External genitalia: Urethral meatus for discharge, blood at meatus, lesions
- Penile shaft: Plaques (Peyronie disease), lesions
- Testes: Masses, tenderness, varicocele
- Digital rectal examination:
- Prostate size (benign prostatic hyperplasia)
- Prostate consistency (hard nodule suggests cancer)
- Prostate tenderness (prostatitis)
- Rectal masses
Female Examination
- External genitalia: Urethral caruncle, urethral prolapse, atrophic changes
- Vaginal examination: Rule out vaginal source of bleeding, masses, prolapse
- Bimanual examination: Pelvic masses, uterine enlargement, adnexal tenderness
- Urethral meatus: Position, discharge, blood
- Note: Ensure urine sample is obtained avoiding menstrual contamination; mid-stream clean catch or catheterized specimen if needed
Extremities and Skin
| Finding | Description | Associated Conditions |
|---|---|---|
| Peripheral edema | Pitting edema of lower extremities, sacral edema if bedbound | Nephrotic syndrome, heart failure, acute kidney injury with fluid overload |
| Palpable purpura | Raised, non-blanching purpuric lesions, typically on lower extremities and buttocks | IgA vasculitis (Henoch-Schönlein purpura), cryoglobulinemia, other small vessel vasculitis |
| Livedo reticularis | Lacy, reticular pattern of skin discoloration | Cholesterol emboli, antiphospholipid syndrome, polyarteritis nodosa |
| Splinter hemorrhages | Linear red-brown streaks under fingernails | Infective endocarditis (associated with immune complex glomerulonephritis) |
| Arthritis | Joint swelling, warmth, restricted range of motion | Systemic lupus erythematosus, IgA vasculitis, reactive arthritis |
| Digital ischemia | Cyanosis, necrosis, or gangrene of digits | Vasculitis, atheroembolic disease, cryoglobulinemia |
Expected Findings by Etiology
| Condition | General | Abdominal/GU | Other Key Findings |
|---|---|---|---|
| Urinary tract infection | Fever, appears uncomfortable | Suprapubic tenderness; costovertebral angle tenderness if pyelonephritis | Usually no other findings |
| Urolithiasis | Restless, writhing, unable to find comfortable position | Costovertebral angle tenderness; minimal abdominal findings | Diaphoresis, tachycardia from pain |
| Bladder cancer | Often normal; cachexia in advanced disease | Usually normal; palpable mass in advanced disease | Lymphadenopathy in metastatic disease |
| Benign prostatic hyperplasia | Normal | Enlarged, smooth, firm prostate on digital rectal examination; palpable bladder if retention | Usually no other findings |
| Acute glomerulonephritis | Edema (periorbital, peripheral), hypertension | Usually non-tender | Signs of fluid overload (elevated jugular venous pressure, crackles, S3) |
| IgA vasculitis (Henoch-Schönlein purpura) | Palpable purpura on lower extremities and buttocks | Abdominal tenderness (bowel involvement) | Arthritis, scrotal swelling in males |
| Polycystic kidney disease | May appear well; hypertension common | Bilateral palpable, nodular kidneys; hepatomegaly (liver cysts) | May have hernias |
| Renal cell carcinoma | Weight loss, pallor; paraneoplastic features possible | Palpable flank mass (late finding); varicocele (left-sided, does not decompress when supine) | Lymphadenopathy, hepatomegaly in metastatic disease |
Important Teaching Point
Normal examination is common! Many significant causes of hematuria present with entirely normal physical examination findings. Bladder cancer, early renal cell carcinoma, glomerulonephritis in early stages, thin basement membrane disease, and IgA nephropathy frequently have no abnormal physical findings. A normal examination does not exclude significant pathology — always proceed with appropriate laboratory and imaging evaluation based on the clinical presentation and risk factors.
5. Differential Diagnosis
Systematic approach organized by probability and clinical features
Gross (Visible) Hematuria
| Probability | Condition | Key Features | Red Flags |
|---|---|---|---|
| COMMON (approximately 60-70%) | Urinary tract infection | Dysuria, frequency, urgency, suprapubic pain, cloudy urine | Fever, flank pain (pyelonephritis) |
| Urolithiasis | Severe colicky flank pain radiating to groin, nausea, restlessness | Fever with obstruction, anuria (bilateral obstruction or solitary kidney) | |
| Benign prostatic hyperplasia (males) | Older male, voiding symptoms, nocturia, weak stream, terminal hematuria | Acute urinary retention, recurrent infections | |
| LESS COMMON (approximately 20-30%) | Bladder cancer | Painless gross hematuria, older age, smoking history, intermittent | Weight loss, bone pain (metastases), any gross hematuria over age 40 |
| Acute glomerulonephritis | Tea-colored urine, edema, hypertension, recent infection | Oliguria, severe hypertension, pulmonary edema | |
| IgA nephropathy | Synpharyngitic hematuria (during or 1-2 days after upper respiratory infection) | Progressive kidney function decline, heavy proteinuria | |
| UNCOMMON BUT SERIOUS (approximately 5-10%) | Renal cell carcinoma | Classic triad (rare): hematuria, flank pain, palpable mass; often incidental | Weight loss, paraneoplastic syndromes, left varicocele |
| Urothelial carcinoma of upper tract | Hematuria, flank pain, older age, smoking history | Hydronephrosis on imaging | |
| Rapidly progressive glomerulonephritis | Hematuria with rapid decline in kidney function over days to weeks | Oliguria, uremia, requires urgent nephrology consultation |
Microscopic Hematuria
Step-by-Step Approach to Microscopic Hematuria:
- Step 1: Confirm true hematuria — repeat urinalysis; rule out contamination (menstruation), pseudohematuria (myoglobinuria, hemoglobinuria, medications)
- Step 2: Determine if glomerular or non-glomerular — examine urine sediment for dysmorphic red blood cells, red blood cell casts, significant proteinuria
- Step 3: Risk stratify for malignancy — age, smoking history, degree of hematuria, occupational exposures
- Step 4: Direct workup accordingly — nephrology referral for glomerular; urology referral for non-glomerular based on risk category
| Probability | Condition | Approximate Frequency | Key Distinguishing Features |
|---|---|---|---|
| COMMON | Idiopathic (no cause found after workup) | 40-50% | Negative complete evaluation; often resolves spontaneously |
| Urinary tract infection | 15-20% | Pyuria, bacteriuria, symptoms of infection; hematuria resolves after treatment | |
| Benign prostatic hyperplasia | 10-15% (in males) | Enlarged prostate, voiding symptoms, older male | |
| Thin basement membrane disease | 5-10% | Persistent microscopic hematuria, family history, normal kidney function, minimal proteinuria | |
| LESS COMMON | Urolithiasis | 5-10% | May be asymptomatic; history of stones; calcium oxalate crystals on urinalysis |
| IgA nephropathy | 5-8% | Episodes of gross hematuria with infections; persistent microscopic hematuria between episodes | |
| Bladder cancer | 2-5% | Risk increases with age, smoking, occupational exposure; higher rates in high-risk patients | |
| UNCOMMON | Renal cell carcinoma | Less than 1% | Usually found incidentally on imaging; hematuria less common presentation than with bladder cancer |
| Alport syndrome | Less than 1% | Family history, hearing loss, progressive kidney disease, eye abnormalities | |
| Polycystic kidney disease | Less than 1% | Family history, palpable kidneys, hypertension, hepatic cysts |
Anatomical Approach to Differential Diagnosis
Glomerular (Kidney)
IgA nephropathy
Thin basement membrane disease
Alport syndrome
Post-infectious glomerulonephritis
Lupus nephritis
Anti-GBM disease
ANCA-associated vasculitis
Non-Glomerular Renal
Renal cell carcinoma
Polycystic kidney disease
Renal stones
Pyelonephritis
Papillary necrosis
Renal infarction
Arteriovenous malformation
Ureter
Ureteral stones
Urothelial carcinoma
Stricture
Ureteropelvic junction obstruction
Retroperitoneal fibrosis
Endometriosis (females)
Bladder, Prostate, Urethra
Bladder cancer
Cystitis (infectious, radiation, interstitial)
Bladder stones
Benign prostatic hyperplasia
Prostate cancer
Urethritis
Urethral stricture or caruncle
Differentiating Glomerular from Non-Glomerular Causes
| Feature | Glomerular Causes | Non-Glomerular (Urological) Causes |
|---|---|---|
| Urine color | Tea-colored, cola-colored, smoky brown | Bright red, pink |
| Blood clots | Absent | Often present |
| Red blood cell morphology | Dysmorphic; acanthocytes greater than 5% | Isomorphic (normal shape) |
| Red blood cell casts | Present (pathognomonic) | Absent |
| Proteinuria | Often significant (greater than 500 mg/day) | Usually absent or trace |
| Associated findings | Hypertension, edema, elevated creatinine | Dysuria, flank pain, urinary symptoms |
| Referral | Nephrology | Urology |
Drug-Induced Hematuria
| Drug or Drug Class | Mechanism | Characteristics | Management |
|---|---|---|---|
| Anticoagulants (warfarin, heparin, direct oral anticoagulants) | Unmasks underlying pathology; does not cause hematuria in normal urinary tract | Any degree of hematuria; supratherapeutic INR increases bleeding but pathology still present | Complete urological workup required; do not attribute solely to anticoagulation |
| Cyclophosphamide | Acrolein metabolite causes hemorrhagic cystitis | Gross hematuria, dysuria, frequency; may occur during or after treatment | Prevention with mesna, hydration; cystoscopy if severe |
| Nonsteroidal anti-inflammatory drugs | Acute interstitial nephritis; papillary necrosis with chronic use | Microscopic hematuria, white blood cell casts, sterile pyuria; flank pain with papillary necrosis | Discontinue offending agent; supportive care |
| Penicillins, cephalosporins, sulfonamides | Acute interstitial nephritis (hypersensitivity reaction) | Fever, rash, eosinophilia, eosinophiluria; onset days to weeks after starting medication | Discontinue drug; corticosteroids may hasten recovery |
| Ketamine (recreational abuse) | Direct bladder toxicity causing ulcerative cystitis | Severe dysuria, frequency, urgency, gross hematuria; contracted bladder | Cessation of ketamine; symptomatic treatment; may require bladder augmentation |
| Radiation therapy (pelvic) | Radiation cystitis; vascular damage to bladder mucosa | Occurs months to years after radiation; recurrent hematuria, telangiectasias on cystoscopy | Hyperbaric oxygen, intravesical therapy, fulguration of telangiectasias |
Quick Reference: “If You See This, Think This”
| Clinical Clue | Think This First | Next Step |
|---|---|---|
| Painless gross hematuria in patient over 50 | Bladder cancer until proven otherwise | Urgent cystoscopy and upper tract imaging |
| Colicky flank pain with hematuria | Ureteral stone | Non-contrast CT abdomen and pelvis |
| Tea-colored urine with edema and hypertension | Acute glomerulonephritis | Urinalysis with microscopy, serum creatinine, nephrology referral |
| Gross hematuria during upper respiratory infection | IgA nephropathy (synpharyngitic) | Urinalysis, kidney function tests, nephrology referral |
| Gross hematuria 10-14 days after pharyngitis | Post-streptococcal glomerulonephritis | ASO titer, complement levels, nephrology referral |
| Hematuria with hemoptysis | Pulmonary-renal syndrome (anti-GBM disease, ANCA vasculitis) | Urgent nephrology and pulmonology; ANCA, anti-GBM antibodies |
| Microscopic hematuria with family history of kidney disease and hearing loss | Alport syndrome | Audiometry, ophthalmology examination, consider kidney biopsy |
| Hematuria with palpable purpura | IgA vasculitis (Henoch-Schönlein purpura) or other vasculitis | Urinalysis, kidney function, skin biopsy if diagnosis uncertain |
| Terminal hematuria with voiding symptoms in older male | Benign prostatic hyperplasia or prostate cancer | Digital rectal examination, PSA, consider urology referral |
| Hematuria in patient from schistosomiasis-endemic area | Schistosomiasis (risk for squamous cell bladder cancer) | Urine microscopy for ova, serology, cystoscopy |
Age-Based Differential Considerations
- Young adults (18-40): UTI, urolithiasis, IgA nephropathy, thin basement membrane disease, exercise-induced hematuria most common
- Middle-aged adults (40-60): UTI, stones, and BPH remain common; increasing concern for malignancy; IgA nephropathy may progress
- Older adults (over 60): Malignancy (bladder, kidney, prostate) becomes a primary concern; BPH very common; always rule out cancer in this age group
6. Diagnostic Investigations
A stepwise, cost-effective approach guided by clinical suspicion
Baseline Investigations for All Patients
| Investigation | Purpose | What to Look For | Practical Points |
|---|---|---|---|
| Urinalysis with microscopy | Confirm hematuria; characterize red blood cells; detect infection, proteinuria | Red blood cell count and morphology (dysmorphic vs isomorphic), red blood cell casts, white blood cells, bacteria, protein, glucose | Examine fresh specimen within 30 minutes; casts degrade quickly; mid-stream clean catch; avoid during menstruation |
| Urine culture | Identify or exclude urinary tract infection | Bacterial growth greater than 10^5 CFU/mL indicates infection; lower counts may be significant with symptoms | Obtain before starting antibiotics; repeat urinalysis after treating UTI to confirm hematuria resolution |
| Serum creatinine and estimated GFR | Assess kidney function | Elevated creatinine suggests glomerular disease, obstruction, or intrinsic renal pathology | Compare to baseline if available; calculate eGFR using CKD-EPI equation |
| Complete blood count | Assess for anemia, infection, or hematological abnormality | Anemia (chronic blood loss, hemolysis, chronic disease); leukocytosis (infection); thrombocytopenia (bleeding diathesis) | Low hemoglobin with hematuria warrants urgent evaluation |
| Coagulation studies (if indicated) | Assess bleeding risk in patients on anticoagulants or with bleeding history | PT/INR, aPTT; supratherapeutic INR increases bleeding but does not explain hematuria | Abnormal coagulation does not obviate need for complete evaluation |
| Urine protein-to-creatinine ratio | Quantify proteinuria; helps distinguish glomerular from non-glomerular | Greater than 500 mg/g suggests significant glomerular pathology | 24-hour urine collection more accurate but spot ratio adequate for screening |
Key Urine Microscopy Findings
- Dysmorphic red blood cells: Variable size and shape; membrane blebs and protrusions; indicates glomerular origin
- Acanthocytes: Ring-shaped red blood cells with vesicle-shaped protrusions; greater than 5% is highly specific for glomerular bleeding
- Red blood cell casts: Pathognomonic of glomerular bleeding; indicates active glomerulonephritis
- White blood cell casts: Suggest pyelonephritis or interstitial nephritis
- Isomorphic red blood cells: Normal biconcave shape; indicates non-glomerular (urological) bleeding
Imaging Studies
| Imaging Modality | Indications | What It Detects | Limitations |
|---|---|---|---|
| CT urography (with and without contrast) | Gold standard for hematuria workup; preferred for suspected malignancy or stones | Renal masses, urothelial tumors, stones, hydronephrosis, renal parenchymal disease | Contrast nephropathy risk; radiation exposure; may miss small urothelial lesions |
| Non-contrast CT (CT KUB) | Suspected urolithiasis; contraindication to contrast | Stones (sensitivity greater than 95%), hydronephrosis, large masses | Cannot characterize soft tissue masses; misses urothelial tumors |
| Renal ultrasound | First-line in low-risk patients; pregnancy; contrast allergy; chronic kidney disease | Hydronephrosis, large renal masses, cysts, bladder abnormalities, post-void residual | Operator dependent; misses small tumors and stones; does not visualize ureters well |
| MR urography | Alternative when CT contraindicated; characterize complex renal masses | Renal masses, urothelial tumors, vascular abnormalities | Expensive; time-consuming; contraindicated with certain implants; gadolinium risk in severe CKD |
| Intravenous pyelogram (IVP) | Largely replaced by CT urography; may still be used where CT unavailable | Filling defects, hydronephrosis, ureteral abnormalities | Lower sensitivity than CT; contrast required; largely obsolete |
Cystoscopy
When to Perform Cystoscopy:
- All patients with gross hematuria (after UTI ruled out or treated)
- Microscopic hematuria with intermediate or high risk for malignancy
- Age greater than 35-40 with unexplained microscopic hematuria
- Any patient with risk factors for bladder cancer (smoking, occupational exposure)
- Persistent hematuria despite negative imaging
- Irritative voiding symptoms with hematuria
| Finding | Appearance | Clinical Significance |
|---|---|---|
| Papillary tumor | Frond-like growth projecting into bladder lumen | Urothelial carcinoma; requires biopsy and staging |
| Sessile tumor | Flat or slightly raised lesion, may be erythematous | Often higher grade; carcinoma in situ appears as red velvety patch |
| Trabeculation | Thickened bladder wall with prominent muscle bands | Chronic outlet obstruction (BPH, stricture) |
| Telangiectasias | Dilated blood vessels on bladder mucosa | Radiation cystitis; source of hematuria |
| Stones | Mobile or fixed calculi in bladder | May cause hematuria and irritative symptoms |
| Lateralizing hematuria | Blood effluxing from one ureteral orifice | Localizes bleeding to ipsilateral upper tract |
Targeted Investigations by Suspected Etiology
If Suspecting Glomerular Disease
First-Line Tests
- Urine protein-to-creatinine ratio: Greater than 500 mg/g suggests significant glomerular disease
- Serum creatinine and eGFR: Assess kidney function
- Serum albumin: Low in nephrotic syndrome
- Complement levels (C3, C4): Low in post-infectious GN, lupus nephritis, MPGN
Second-Line Tests
- ANA, anti-dsDNA: Systemic lupus erythematosus
- ANCA (PR3, MPO): ANCA-associated vasculitis
- Anti-GBM antibody: Anti-glomerular basement membrane disease
- ASO titer: Post-streptococcal glomerulonephritis
- Hepatitis B and C serology: Associated glomerulonephritis
- Kidney biopsy: Definitive diagnosis when indicated
If Suspecting Urological Malignancy
First-Line Tests
- CT urography: Evaluates kidneys, ureters, and bladder in single study
- Cystoscopy: Direct visualization of bladder; biopsy suspicious lesions
- Urine cytology: May detect high-grade urothelial carcinoma; low sensitivity for low-grade tumors
Second-Line Tests
- Ureteroscopy: When upper tract lesion suspected but not seen on imaging
- Retrograde pyelography: Evaluate ureteral filling defects
- Urine tumor markers: NMP22, BTA, UroVysion FISH; may supplement cytology
- Blue light cystoscopy: Enhanced detection of carcinoma in situ
If Suspecting Urolithiasis
First-Line Tests
- Non-contrast CT abdomen and pelvis: Gold standard; sensitivity greater than 95% for stones of any composition
- Urinalysis: Crystals may suggest stone type (calcium oxalate, uric acid, struvite)
Metabolic Evaluation (for recurrent stones)
- 24-hour urine collection: Calcium, oxalate, citrate, uric acid, sodium, creatinine, pH
- Serum calcium, phosphorus, uric acid: Screen for metabolic causes
- Parathyroid hormone: If hypercalcemia detected
- Stone analysis: Composition guides prevention strategy
Risk-Based Approach to Microscopic Hematuria (AUA Guidelines)
| Risk Category | Criteria | Recommended Evaluation |
|---|---|---|
| LOW RISK | Age less than 40; never smoker or less than 10 pack-years; 3-10 RBC/HPF; no risk factors | Repeat urinalysis in 6 months; may defer imaging and cystoscopy; shared decision-making with patient |
| INTERMEDIATE RISK | Age 40-59; 10-30 pack-years; 11-25 RBC/HPF; low-risk with prior negative evaluation | Renal ultrasound AND cystoscopy; CT urography may be substituted for ultrasound |
| HIGH RISK | Age 60 or older; greater than 30 pack-years; greater than 25 RBC/HPF; gross hematuria history | CT urography AND cystoscopy; most complete evaluation warranted |
When to Refer
Urology Referral
- All gross hematuria (after UTI excluded)
- Microscopic hematuria with intermediate or high risk
- Abnormal imaging (mass, filling defect)
- Positive urine cytology
- Recurrent UTI with hematuria
- Voiding symptoms requiring further evaluation
Nephrology Referral
- Dysmorphic red blood cells or red blood cell casts
- Significant proteinuria (greater than 500 mg/day)
- Elevated or rising serum creatinine
- Hypertension with hematuria
- Systemic symptoms suggesting glomerulonephritis
- Family history of hereditary nephropathy
Common Investigation Pitfalls
- Attributing hematuria to anticoagulation: Patients on anticoagulants require full workup; anticoagulation unmasks pathology, it does not cause it
- Stopping evaluation after treating UTI: Always repeat urinalysis after UTI treatment to confirm hematuria has resolved; persistent hematuria requires further evaluation
- Relying on ultrasound alone in high-risk patients: Ultrasound misses many urothelial tumors and small renal masses; use CT urography for high-risk patients
- Omitting cystoscopy: Imaging alone is insufficient; cystoscopy is required to evaluate the bladder in patients at risk for malignancy
- Single negative evaluation: If initial workup is negative but hematuria persists, repeat evaluation in 12 months or sooner if gross hematuria develops
7. Pattern Recognition and Clinical Decision-Making
Practical algorithms and decision pathways
Step 1: Is This Urgent?
| Clinical Scenario | Urgency Level | Immediate Action |
|---|---|---|
| Gross hematuria with hemodynamic instability | EMERGENT | IV access, fluid resuscitation, type and screen, urgent urology consult, consider ICU admission |
| Clot retention with inability to void | EMERGENT | Large-bore (22-24 Fr) three-way catheter, continuous bladder irrigation, urgent urology consult |
| Hematuria with acute kidney injury and oliguria | EMERGENT | Urgent nephrology consult, assess for rapidly progressive glomerulonephritis, consider dialysis if indicated |
| Hematuria with hemoptysis (pulmonary-renal syndrome) | EMERGENT | Urgent nephrology and pulmonology, ANCA and anti-GBM antibodies, prepare for possible plasmapheresis |
| Gross hematuria with fever and flank pain | URGENT | Blood and urine cultures, IV antibiotics, imaging to rule out obstruction or abscess |
| Painless gross hematuria in patient over 40 | URGENT | Expedited urology referral for cystoscopy and CT urography within 2 weeks |
| Microscopic hematuria with normal kidney function, no proteinuria | ROUTINE | Risk stratify; schedule appropriate workup based on risk category; repeat urinalysis if low risk |
| Transient microscopic hematuria in young, healthy patient | ROUTINE | Repeat urinalysis in 6 weeks; if resolved, no further workup needed; if persistent, risk stratify |
Step 2: Classify the Hematuria
By Visibility
Gross hematuria: Visible blood — always requires complete evaluation
Microscopic hematuria: ≥3 RBC/HPF — risk stratify to guide workup intensity
By Source
Glomerular: Dysmorphic RBCs, casts, proteinuria → Nephrology pathway
Non-glomerular: Isomorphic RBCs, clots, no casts → Urology pathway
By Duration
Transient: May observe in low-risk patients
Persistent: Present on 2+ occasions — requires evaluation
Step 3: Follow the Appropriate Pathway
Pathway A: Gross Hematuria Algorithm
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Gross hematuria + dysuria + frequency + fever | Urinary tract infection or pyelonephritis | Urine culture, treat infection, repeat urinalysis after treatment; if hematuria persists, proceed to full workup |
| Gross hematuria + severe colicky flank pain | Ureteral stone | Non-contrast CT abdomen/pelvis, pain control, urology referral if stone unlikely to pass |
| Painless gross hematuria + age over 40 + smoking history | Bladder cancer until proven otherwise | CT urography + cystoscopy within 2 weeks; urology referral |
| Gross hematuria + voiding symptoms + enlarged prostate | Benign prostatic hyperplasia (or prostate cancer) | PSA, digital rectal exam, urology referral; still requires cystoscopy to exclude bladder cancer |
| Tea-colored urine + edema + hypertension + recent infection | Acute glomerulonephritis | Urgent nephrology referral, serum creatinine, complement levels, urinalysis with microscopy |
| Gross hematuria during or immediately after upper respiratory infection | IgA nephropathy | Nephrology referral, check kidney function, urine protein quantification |
Pathway B: Microscopic Hematuria Algorithm
| Clinical Scenario | Risk Category | Action |
|---|---|---|
| Age less than 40, non-smoker, 3-10 RBC/HPF, no risk factors | LOW RISK | Shared decision-making; may repeat urinalysis in 6 months OR proceed with renal ultrasound; cystoscopy optional |
| Age 40-59, 10-30 pack-years smoking, 11-25 RBC/HPF | INTERMEDIATE RISK | Renal ultrasound AND cystoscopy; or CT urography AND cystoscopy |
| Age 60+, heavy smoker, greater than 25 RBC/HPF | HIGH RISK | CT urography AND cystoscopy; complete evaluation mandatory |
| Any age with dysmorphic RBCs, RBC casts, or significant proteinuria | GLOMERULAR | Nephrology referral; serological workup; consider kidney biopsy |
| Microscopic hematuria with active UTI | DEFERRED | Treat UTI; repeat urinalysis 6 weeks after treatment; if hematuria resolves, no further workup; if persists, risk stratify |
“What Do I Do If…” Decision Reference
| Clinical Situation | Immediate Action | Next Step |
|---|---|---|
| Patient on anticoagulation with new hematuria | Do NOT attribute to anticoagulation alone | Complete urological workup same as any patient; anticoagulation unmasks pathology |
| Hematuria resolved after treating UTI | Confirm resolution with repeat urinalysis at 6 weeks | If resolved, no further workup; if persistent, proceed with risk-appropriate evaluation |
| Negative initial workup but hematuria persists | Continue surveillance | Repeat urinalysis annually for at least 2 years; repeat imaging and cystoscopy at 12 months if high risk or gross hematuria recurs |
| Patient refuses cystoscopy | Document discussion of risks including missed bladder cancer | Offer urine cytology (lower sensitivity); close follow-up with repeat urinalysis; strongly encourage cystoscopy |
| Positive urine cytology but negative cystoscopy and imaging | Refer to urology for further evaluation | Consider ureteroscopy to evaluate upper tracts; blue light cystoscopy; repeat evaluation in 3-6 months |
| Young patient with isolated microscopic hematuria and family history of kidney disease | Consider inherited nephropathy | Nephrology referral; audiometry; ophthalmology exam; genetic testing if Alport syndrome suspected |
| Exercise-induced gross hematuria | Reassure; typically resolves within 24-72 hours | Repeat urinalysis after 72 hours of rest; if resolved, counsel on hydration; if persistent, proceed with standard workup |
| Menstruating patient with microscopic hematuria | Repeat urinalysis when not menstruating | If hematuria persists when repeated mid-cycle, proceed with standard workup |
Troubleshooting Persistent or Recurrent Hematuria
Ask These Questions When Hematuria Persists Despite Negative Workup
- Was the evaluation complete? Did it include both upper tract imaging AND cystoscopy?
- Was the imaging adequate? Ultrasound may miss small tumors; consider CT urography if not done
- Was glomerular disease excluded? Was urine examined for dysmorphic RBCs and casts? Was proteinuria quantified?
- Could there be a sampling error? Intermittent lesions may be missed; consider repeat cystoscopy
- Is there an upper tract lesion? Consider ureteroscopy if imaging negative but suspicion remains
- Is the patient high risk? High-risk patients warrant more aggressive and repeated evaluation
- Has enough time passed? Some lesions become apparent only on follow-up; continue surveillance
Follow-Up After Negative Initial Evaluation
| Initial Presentation | Follow-Up Schedule | Indications to Re-Evaluate |
|---|---|---|
| Low-risk microscopic hematuria with negative workup | Repeat urinalysis at 12 months; if resolved, may discharge; if persistent, repeat at 12-month intervals for 2 years | Development of gross hematuria, new risk factors, increasing RBC count |
| Intermediate-risk microscopic hematuria with negative workup | Repeat urinalysis at 12 months; consider repeat imaging and cystoscopy if hematuria persists | Persistent hematuria after 2 years, gross hematuria, new symptoms |
| High-risk microscopic hematuria with negative workup | Repeat urinalysis at 6-12 months; repeat CT urography and cystoscopy at 12 months if hematuria persists | Any persistence warrants repeat evaluation; low threshold for ureteroscopy |
| Gross hematuria with negative workup | Repeat urinalysis at 6 months; repeat imaging and cystoscopy at 12 months or sooner if recurs | Any recurrence of gross hematuria requires immediate re-evaluation |
8. Clinical Pearls and Pitfalls
Practical wisdom — learn from successes and avoid common mistakes
Must-Know Clinical Pearls
Painless gross hematuria is bladder cancer until proven otherwise: In patients over age 40, painless visible hematuria has a 10-20% chance of being caused by urological malignancy. Always pursue cystoscopy and upper tract imaging expeditiously.
Anticoagulation unmasks, it does not cause: Patients on warfarin, direct oral anticoagulants, or antiplatelet agents who develop hematuria have the same rate of significant underlying pathology as patients not on these medications. Never attribute hematuria to anticoagulation alone.
Clots exclude glomerular bleeding: Blood clots cannot form if bleeding originates from the glomerulus because urokinase in the tubules lyses any forming clots. Presence of clots definitively points to a non-glomerular (urological) source.
Synpharyngitic versus post-infectious timing matters: IgA nephropathy causes hematuria during or within 1-2 days of upper respiratory infection (synpharyngitic), while post-streptococcal glomerulonephritis occurs 10-14 days after pharyngitis. This timing distinction helps differentiate the diagnoses.
Red blood cell casts are pathognomonic: The presence of red blood cell casts on urine microscopy is pathognomonic of glomerular bleeding and indicates active glomerulonephritis. This finding alone warrants urgent nephrology referral.
Smoking is the strongest modifiable risk factor for bladder cancer: Smoking accounts for approximately 50% of bladder cancer cases. Always quantify smoking history in pack-years when evaluating hematuria.
Both nephrology AND urology evaluation may be needed: Some patients have concurrent glomerular disease and urological pathology. If features of both are present (for example, proteinuria with clots), refer to both specialists.
A single normal urinalysis does not exclude hematuria: Hematuria can be intermittent, especially with malignancy. If clinical suspicion is high, repeat testing is warranted even after a single negative result.
Critical Pitfalls to Avoid
Stopping evaluation after treating UTI: Always confirm hematuria has resolved with a repeat urinalysis 6 weeks after completing antibiotic treatment. Persistent hematuria after UTI treatment requires complete evaluation to exclude coexisting pathology.
Relying on ultrasound alone in high-risk patients: Renal ultrasound has limited sensitivity for small renal masses, urothelial tumors, and ureteral pathology. High-risk patients require CT urography for adequate evaluation of the upper tracts.
Omitting cystoscopy: Imaging alone cannot adequately evaluate the bladder. Cystoscopy is required in all patients at intermediate or high risk for malignancy, and in all patients with gross hematuria. Many bladder cancers are missed on imaging.
Assuming benign prostatic hyperplasia explains hematuria: While BPH can cause hematuria, bladder cancer is more common in the same demographic. Always perform cystoscopy to exclude malignancy, even when BPH is present.
Ignoring microscopic hematuria in young patients: While malignancy is rare in young adults, glomerular diseases like IgA nephropathy and thin basement membrane disease are common and can progress. Young patients with persistent microscopic hematuria deserve evaluation.
Forgetting to examine fresh urine: Red blood cell casts and dysmorphic red blood cells degrade within 1-2 hours. Urine should be examined within 30 minutes of collection for optimal sensitivity in detecting glomerular disease.
Not confirming true hematuria before extensive workup: Red urine is not always hematuria. Confirm the presence of red blood cells on microscopy before ordering imaging and cystoscopy. Rule out pseudohematuria from hemoglobinuria, myoglobinuria, medications, or foods.
Abandoning surveillance after one negative evaluation: Some urological malignancies are intermittently detectable. Patients with persistent hematuria and initial negative workup require ongoing surveillance with repeat urinalysis and consideration of repeat imaging and cystoscopy.
Key Takeaways
- Hematuria is classified as gross (visible) or microscopic (≥3 RBC/HPF); gross hematuria always requires complete evaluation regardless of patient age or risk factors
- Distinguish glomerular from non-glomerular hematuria using urine microscopy: dysmorphic red blood cells, red blood cell casts, and significant proteinuria indicate glomerular disease requiring nephrology referral
- Painless gross hematuria in adults over 40 is urological malignancy until proven otherwise; expedite cystoscopy and CT urography
- Risk stratify patients with microscopic hematuria using age, smoking history, and degree of hematuria to guide evaluation intensity
- Anticoagulation does not cause hematuria in a normal urinary tract — it unmasks underlying pathology; complete evaluation is required
- A complete hematuria evaluation includes upper tract imaging (CT urography preferred) AND cystoscopy; imaging alone is insufficient
- Always repeat urinalysis after treating UTI to confirm hematuria resolution; persistent hematuria requires further workup
- Consider both urological and nephrological causes; some patients require dual referral when features of both are present
- A normal physical examination is common and does not exclude significant pathology including malignancy
- Patients with negative initial evaluation but persistent hematuria require ongoing surveillance with repeat urinalysis and consideration of repeat imaging and cystoscopy
Quick Reference Algorithm
Systematic Approach to Hematuria:
- Confirm true hematuria: Verify ≥3 RBC/HPF on microscopy; rule out pseudohematuria and contamination
- Assess urgency: Hemodynamic instability, clot retention, acute kidney injury, or pulmonary-renal syndrome require emergent management
- Classify the source: Examine urine sediment for dysmorphic RBCs, casts, and proteinuria to distinguish glomerular from non-glomerular bleeding
- Risk stratify: Use age, smoking history, and RBC count to categorize as low, intermediate, or high risk for malignancy
- Order appropriate investigations: Baseline labs for all; CT urography and cystoscopy for intermediate/high risk and all gross hematuria; nephrology workup if glomerular features present
- Refer appropriately: Urology for non-glomerular causes and malignancy evaluation; nephrology for glomerular disease; sometimes both are needed
- Ensure follow-up: Repeat urinalysis after UTI treatment; surveillance with repeat urinalysis at 6-12 months if initial workup negative but hematuria persists